MedTrace Logo

Safety and Efficacy of AMG 827 in Subjects With RA

NCT01059448 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2022-02-28

Study results available
· View outcomes & findings →

Summary

This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.

Conditions

Interventions

DRUG

AMG 827

AMG 827 210 mg

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-03
Primary Completion
2011-04-05
Completion
2011-04-05

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Latvia
  • Mexico
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059448 on ClinicalTrials.gov